SNTS Related Guidance
-
Santarus (SNTS) Tops Q1 EPS by 18c; Boosts FY13 Outlook
-
Santarus, Inc. (SNTS) Tops Q4 EPS by 7c; Issues Strong FY13 EPS Outlook
-
Santarus (SNTS) Receives FDA Approval of UCERIS; Sees Strong FY12, FY13 Revs
-
Santarus, Inc. (SNTS) Tops Q3 EPS by 3c, Raises Guidance
-
Santarus, Inc. (SNTS) Tops Q1 EPS by 3c; Sees FY12 Revs Above Views
-
Santarus (SNTS) Enters Agreement to Commercialize FENOGLIDE(R) in US; Offers FY12 Sales Guidance
-
Santarus, Inc. (SNTS) Tops Q2 EPS by 4c; Guides FY11 Revs
-
Santarus Inc. (SNTS) Tops Q4 EPS by 25c
-
Santarus Inc. (SNTS) Posts Q3 GAAP Loss of $0.44; Revs Light; Guides FY10 Revs Below Street
-
Santarus Inc. (SNTS) Posts Q4 EPS of $0.40, Tops Views; Guides FY10 Sales Above Street
-
Santarus (SNTS) Tops Q2 Views; Affirms FY09 Sales Guidance
-
Santarus (SNTS) Reports Q3 Loss of $0.08, Beats by 1c; Raises FY08 Sales Outlook
-
Santarus (SNTS) Tops Q2 EPS by 12c, Affirms FY Revenue Outlook
-
Santarus, Inc. (SNTS) Reports In-Line; Issues Lower Guidance
-
Santarus (SNTS) Sees Addition of Sales Positions, Guides for Up Second Half of year
-
Santarus (SNTS) Tops Q3 EPS by 10c
Back to SNTS Stock Lookup
